Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimiliano Bonifacio

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Expert Opinion on Pharmacotherapy|May 13, 2024
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Current Pharmaceutical Design|October 26, 2016
Mast Cell Disorders In Drug HypersensitivityPatrizia Bonadonna, Massimiliano Bonifacio, Roberta Zanotti
Current Allergy and Asthma Reports|December 31, 2015
Hymenoptera Allergy and Mast Cell Activation SyndromesPatrizia Bonadonna, Massimiliano Bonifacio, Carla Lombardo, et al.
Current Allergy and Asthma Reports|July 8, 2015
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected AssociationPatrizia Bonadonna, Massimiliano Bonifacio, Carla Lombardo, et al.
British Journal of Haematology|August 31, 2019
A journey through infectious risk associated with ruxolitinibEmanuela Sant'Antonio, Massimiliano Bonifacio, Massimo Breccia, et al.
Expert Review of Hematology|March 25, 2016
Immunotherapy approaches to treat adult acute lymphoblastic leukemiaElena Maino, Massimiliano Bonifacio, Anna Maria Scattolin, et al.
Bone Marrow Transplantation|September 20, 2019
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based reviewMario Tiribelli, Francesca Palandri, Emanuela Sant'Antonio, et al.
Immunology and Allergy Clinics of North America|July 16, 2018
Bone Disease in MastocytosisGiovanni Orsolini, Ombretta Viapiana, Maurizio Rossini, et al.
Frontiers in Oncology|November 12, 2019
Management of Chronic Myeloid Leukemia in Advanced PhaseMassimiliano Bonifacio, Fabio Stagno, Luigi Scaffidi, et al.
Pharmacoeconomics - Open|July 23, 2021
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in ItalyMassimiliano Bonifacio, Vikalp Maheshwari, Diana Tran, et al.
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Expert Opinion on Pharmacotherapy|May 13, 2024
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Current Pharmaceutical Design|October 26, 2016
Mast Cell Disorders In Drug HypersensitivityPatrizia Bonadonna, Massimiliano Bonifacio, Roberta Zanotti
Current Allergy and Asthma Reports|December 31, 2015
Hymenoptera Allergy and Mast Cell Activation SyndromesPatrizia Bonadonna, Massimiliano Bonifacio, Carla Lombardo, et al.
Current Allergy and Asthma Reports|July 8, 2015
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected AssociationPatrizia Bonadonna, Massimiliano Bonifacio, Carla Lombardo, et al.
British Journal of Haematology|August 31, 2019
A journey through infectious risk associated with ruxolitinibEmanuela Sant'Antonio, Massimiliano Bonifacio, Massimo Breccia, et al.
Expert Review of Hematology|March 25, 2016
Immunotherapy approaches to treat adult acute lymphoblastic leukemiaElena Maino, Massimiliano Bonifacio, Anna Maria Scattolin, et al.
Bone Marrow Transplantation|September 20, 2019
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based reviewMario Tiribelli, Francesca Palandri, Emanuela Sant'Antonio, et al.
Immunology and Allergy Clinics of North America|July 16, 2018
Bone Disease in MastocytosisGiovanni Orsolini, Ombretta Viapiana, Maurizio Rossini, et al.
Frontiers in Oncology|November 12, 2019
Management of Chronic Myeloid Leukemia in Advanced PhaseMassimiliano Bonifacio, Fabio Stagno, Luigi Scaffidi, et al.
Pharmacoeconomics - Open|July 23, 2021
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in ItalyMassimiliano Bonifacio, Vikalp Maheshwari, Diana Tran, et al.
Pageof 17